CGTLive’s Weekly Rewind – September 22, 2023

News
Article

Review top news and interview highlights from the week ending September 22, 2023.

Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Taysha Gene Therapies Drops Development of Giant Axonal Neuropathy Gene Therapy TSHA-120

The company is now prioritizing its gene therapy program for Rett syndrome.

2. Pat Furlong, BSN, RN, on the State of Gene Therapy in Muscular Dystrophy

The founding president and chief executive officer of Parent Project Muscular Dystrophy discussed recent and upcoming milestones in the field.

3. Research Identifies Cell Signatures of CAR T-Cells in Long Remission

Cells from patients with ALL treated in the CARPALL study were analyzed and sequenced.

4. Deborah Phippard, PhD, on the History and Current State of Gene Therapy for Neurological Indications

The chief scientific officer of Precision for Medicine discussed the previous and current delivery methods used for gene therapies and new innovations on the horizon.

5. Orchard Therapeutics’ BLA for Metachromatic Leukodystrophy Cell Therapy Arsa-Cel Accepted With Priority Review

The PDUFA data has been set for March 18, 2024.

Related Videos
Evan Weber, PhD, an assistant professor of pediatrics at Children's Hospital of Philadelphia
Shankar Ramaswamy, MD, the cofounder, chairman, and CEO of Kriya Therapeutics
Kevin Campbell, PhD, a Howard Hughes Investigator at the University of Iowa
Debora Mazzetti, MS, on Multitargeting MicroRNA in Glioblastoma
Francesca Del Bufalo, MD, PhD, a medical doctor and scientist at Bambino Gesù Chidren’s Hospital
Travis Drow, BS, a research scientist at Seattle Children's Research Institute
Carlos Ramos, MD, on Alternatives to T-Cell Therapy
Omer A. Abdul Hamid, MD, on Sharing Expertise With Gene Therapy Logistics
Jeffrey Chamberlain, PhD, on Bringing Back the Focus to Basic Research for ASGCT 2024
Omid Hamid, MD
© 2024 MJH Life Sciences

All rights reserved.